links header

Pulmonary Transplantation Highlights from Prague

David Weill, MD
Pulmonary Transplantation Council Chair

Printer Friendly PDF


david weillThe Prague meeting provided sessions that were highly interesting for the lung transplant community. All the lung sessions were well attended, with outstanding participation during the question and answer periods.

Of particular interest were the discussions about antibody-mediated rejection (AMR), which focused on the diagnosis, natural history, and treatment for this rapidly evolving clinical challenge. Although there is currently no consensus about many of the important issues with regard to AMR, a robust discussion is clearly occurring within the lung transplant community that will undoubtedly lead to more clarity on these vexing challenges. In the coming year, a closer collaboration between the Pulmonary Transplantation Council and the Pathology Council should lead to further understanding of AMR and hopefully a more systematic approach in terms of diagnosis and treatment.

There was also an excellent panel discussion regarding lung transplantation in pulmonary hypertension patients. Postoperative management was thoroughly reviewed, as was using ECMO therapy as a bridge to transplant in these patients and as a modality to stabilize patients during the transplant surgery and in the early postoperative period.

Other important highlights included a session reviewing what is known about the impact of the community acquired respiratory viruses on the development of acute and chronic rejection as well as an outstanding update on post-transplant lymphoproliferative disease.

Overall, the Annual Meeting continues to be an important way for junior and senior physicians and surgeons to find out what's new in our field, and I would like to commend the Scientific Program Chair, Stuart Sweet, and the 2012 Program Committee for once again delivering an excellent Program.

Disclosure Statement: The author has no conflicts of interest to disclose.